The FDA will carry out a priority review of Sanofi's (SNY) Eliglustat pill for Gaucher disease, a rare genetic disorder in which sufferers are deficient in an enzyme that breaks down a certain type of fat.
Sanofi lower after presenting new U300 data. Sanofi (SNY -2.5%) trades lower on the session after the company presented data on U300, an improved version of Lantus which the company hopes can take the edge off the latter's looming patent expiration.
Sanofi (SNY) has halted studies of its Fedratinib treatment for rare bone-marrow cancers, due to safety concerns. The move follows reports of trial patients displaying symptoms associated with the neurological disorder Wernicke's encephalopathy ...
Let's take a look at three stocks - Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Sanofi SA (ADR) (NYSE:SNY), and GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) - which could loom large in health care headlines this morning.
Sanofi SA (ADR) (NYSE:SNY) gained 0.76%, trading on 3.08 million shares, to end the trade at $52.99. The stock changed hands in a range of $52.61 to $53.05, bringing its market capitalization to about $141.18 billion.
After months of muted progress JAK inhibitors and myelofibrosis are hotting up again just in time for next month's American Society of Hematology meeting, although the days when the space was the subject of frenetic deal activity are probably behind it.